BTK and B-cell chronic lymphocytic leukemia: Since then, another BTK inhibitor, acalabrutinib, two phosphatidylinositol-3-kinase (PI3K) inhibitors, idelalisib and duvelisib, and a B-cell lymphoma 2 (BCL-2) inhibitor, venetoclax, have also been approved for CLL [1].